Leuject (Cladribine)

Cladribine is taken up by cells and phosphorylated to an active triphosphate that becomes incorporated into DNA. This incorporation causes DNA strand breaks and triggers programmed cell death, especially in lymphocytes that have high kinase activity, thereby decreasing the number of malignant or autoreactive cells.

The dose of Leuject is determined by the prescribing clinician based on the specific indication, patient weight, disease severity and laboratory parameters. No fixed regimen is provided here; the prescriber will set the appropriate dosing schedule.

Safety data for cladribine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made together with a qualified healthcare professional.

To request Leuject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

For hairy cell leukemia, alternatives such as rituximab or purine analogs like pentostatin are used; cladribine offers a convenient dosing schedule and a distinct mechanism targeting DNA synthesis. In multiple sclerosis, disease‑modifying therapies like interferon‑beta or dimethyl fumarate act through immunomodulation, whereas cladribine provides a short‑course, lymphocyte‑depleting approach.

Leuject must be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the product. Do not use if the solution appears discoloured or if the cold chain has been broken.

Leuject is given as a subcutaneous injection, typically by a trained healthcare professional. The injection is performed into the subcutaneous tissue of the abdomen or thigh using aseptic technique, and the prescribed dosing interval is followed as directed by the prescriber.

The most serious risks include severe or opportunistic infections due to profound lymphopenia, prolonged depletion of lymphocytes that can impair immune function, and rare immune‑mediated liver injury such as autoimmune hepatitis. Patients should be monitored closely for signs of infection or liver dysfunction.

Leuject should be avoided in patients with active, uncontrolled infections, severe immunodeficiency, known hypersensitivity to cladribine, or in pregnant women unless the benefit outweighs the risk. Caution is also advised for individuals with significant liver disease or those receiving other myelosuppressive therapies.